P020 Beyond the Surface: Innovations and Cutting-Edge Therapies in Non-Melanoma Skin Cancer
DESCRIPTION
This session will explore the latest advancements and cutting-edge therapeutic techniques in the diagnosis, prognostication, and treatment of non-melanoma skin cancers. Topics will include diagnostics, prognostication, surgical approaches, non-invasive treatments, and novel systemic therapies. Attendees will gain insights into the clinical application of these techniques and their potential to improve patient outcomes.
LEARNING OBJECTIVES
Examine the latest advancements in diagnostic tools and prognostic markers for non-melanoma skin cancers, and assess how these innovations can improve early detection and individualized treatment plans.
Identify and evaluate the latest advancements in therapeutic techniques for the treatment of non-melanoma skin cancer.
Discuss the future directions and potential applications of emerging technologies in the management and treatment of non-melanoma skin cancers.
SCHEDULE
8:30 PM
Cutting-Edge Prognostication Tools for NMSC
David R. Carr, MD, MPH, FAAD
8:45 PM
NMSC in Immunosuppressed Patients: Evolving Paradigms
Kathryn Shahwan, MD, FAAD
9:00 PM
Use of Energy Based Devices for Photodamage and NMSC
Patricia Richey, MD, FAAD
9:15 PM
Q&A Session 1
9:25 PM
Innovations in NMSC Imaging Techniques and Artificial Intelligence
Mary Elizabeth Lohman, MD, FAAD
9:40 PM
Exploring the Controversy: Superficial Radiation Therapy
Basia M. Michalski, MD, FAAD
9:55 PM
What's New in Systemic Therapy for NMSC
Claire Verschraegen
10:20 PM
Q&A Session 2
SPEAKERS
David R. Carr, MD, MPH, FAAD
The Ohio State University College of Medicine
Mary Elizabeth Lohman, MD, FAAD
Mayo Clinic, Rochester, MN
Basia M. Michalski, MD, FAAD
Washington University in St. Louis
Patricia Richey, MD, FAAD
Kathryn Shahwan, MD, FAAD
Claire Verschraegen
Ohio State University Comprehensive Cancer Center
SPEAKER DISCLOSURES
David R. Carr, MD, MPH, FAAD
Regeneron – Investigator(No Compensation Received);
Mary Elizabeth Lohman, MD, FAAD
No financial relationships exist with ineligible companies.
Basia M. Michalski, MD, FAAD
No financial relationships exist with ineligible companies.
Patricia Richey, MD, FAAD
No financial relationships exist with ineligible companies.
Kathryn Shahwan, MD, FAAD
No financial relationships exist with ineligible companies.
Claire Verschraegen
Sun Pharmaceutical Industries Ltd. – Other(Honoraria);